Jiangsu Xianlin Life Technology Innovation Park Development

The firm operates as a corporate investor with a real estate development core. Nanjing Southeast State-owned Assets Investment Group holds a significant stake, and the park generates exposure to life-science ventures through its incubator facilities and tenant relationships rather than through a conventional fund structure. Its returns are tied to both property performance and the success of the companies that lease lab and office space.

Nanjing University and Nanjing University of Traditional Chinese Medicine serve as academic and research partners located in Xianlin University City. They supply the park with talent, joint research opportunities, and a pipeline of spinout companies that become tenants within the innovation park's lab and office facilities.

The firm's model centers on direct engagement with portfolio companies as tenants and incubator residents. The Jiangsu High-tech Entrepreneurship Service Center co-built a state-level incubator on-site, creating a mechanism for the park to support startups directly without operating a traditional venture capital fund that makes third-party limited partner commitments.

The park focuses on life sciences, biomedical innovation, and pharmaceutical development. Tenant companies such as Jiangsu Aidea Pharmaceutical and Nanjing Ansailai Pharmaceutical Technology indicate a concentration on drug development and related biotech fields within the broader life-science ecosystem.

Specific named principals responsible for investment decisions have not been publicly disclosed. The Jiangsu Life Science & Technology Innovation Park Management Committee, a government-led body, oversees the park's strategic direction, while Nanjing Southeast State-owned Assets Investment Group's significant equity stake suggests influence over major capital allocation decisions.